Dual roles of CD40 on microbial containment and the development of immunopathology in response to persistent fungal infection in the lung

American Journal of Pathology

Volumn 177, Issue 5, 2010, Pages 2459-2471

  Chen, Gwo Hsiao ^a,b   Osterholzer, John J ^a,b   Choe, Mun Y ^a   McDonald, Roderick A ^a   Olszewski, Michal A ^a,b   Huffnagle, Gary B ^a   Toews, Galen B ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN E;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LEUKOCYTE; LUNG MYCOSIS; MACROPHAGE; MOUSE; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH2 CELL;

EID: 78149312230     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100141     Document Type: Article

References (72)

1. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009, 229:152-172
2. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ: CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004, 22:307-328
3. van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000, 67:2-17
4. Ma DY, Clark EA: The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 2009, 21:265-272
5. Suttles J, Stout RD: Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol 2009, 21:257-264
6. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR: CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 1996, 4:283-289
7. Kamanaka M, Yu P, Yasui T, Yoshida K, Kawabe T, Horii T, Kishimoto T, Kikutani H: Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity 1996, 4:275-281
8. Soong L, Xu JC, Grewal IS, Kima P, Sun J, Longley BJ Jr, Ruddle NH, McMahon-Pratt D, Flavell RA: Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 1996, 4:263-273
9. Chaussabel D, Jacobs F, de Jonge J, de Veerman M, Carlier Y, Thielemans K, Goldman M, Vray B: CD40 ligation prevents Trypanosoma cruzi infection through interleukin-12 upregulation. Infect Immun 1999, 67:1929-1934
10. MacDonald AS, Patton EA, La Flamme AC, Araujo MI, Huxtable CR, Bauman B, Pearce EJ: Impaired Th2 development and increased mortality during Schistosoma mansoni infection in the absence of CD40/CD154 interaction. J Immunol 2002, 168:4643-4649
11. Netea MG, Meer JW, Verschueren I, Kullberg BJ: CD40/CD40 ligand interactions in the host defense against disseminated Candida albicans infection: the role of macrophage-derived nitric oxide. Eur J Immunol 2002, 32:1455-1463
12. Hernandez-Novoa B, Bishop L, Logun C, Munson PJ, Elnekave E, Rangel ZG, Barb J, Danner RL, Kovacs JA: Immune responses to Pneumocystis murina are robust in healthy mice but largely absent in CD40 ligand-deficient mice. J Leukoc Biol 2008, 84:420-430
13. + T cells. J Immunol 2001, 167:5603-5609
14. Shedlock DJ, Whitmire JK, Tan J, MacDonald AS, Ahmed R, Shen H: Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection. J Immunol 2003, 170:2053-2063
15. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A: Interleukin 12 is required for the T lymphocyte-independent induction of interferon γ by an intracellular parasite and induces resistance in T cell-deficient hosts, Proc Natl Acad Sci USA 1993, 90:6115-6119
16. + CTL response. J Exp Med 1996, 183:2129-2142
17. Whitmire JK, Slifka MK, Grewal IS, Flavell RA, Ahmed R: CD40 ligand-deficient mice generate a normal primary cytotoxic T lymphocyte response but a defective humoral response to a viral infection. J Virol 1996, 70:8375-8381
18. Wheat LJ, Durkin M, Schnizlein-Bick C, Bassey E, Kohler S, Connolly P, Goldberg J, Garringer T, Brizendine E, Thomas EK: Effect of CD40 ligand on the course of murine histoplasmosis. Med Mycol 2002, 40:501-505
19. Zhou P, Seder RA: CD40 ligand is not essential for induction of type 1 cytokine responses or protective immunity after primary or secondary infection with histoplasma capsulatum. J Exp Med 1998, 187:1315-1324 (Pubitemid 28189120)
20. Campos-Neto A, Ovendale P, Bement T, Koppi TA, Fanslow WC, Rossi MA, Alderson MR: CD40 ligand is not essential for the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis. J Immunol 1998, 160:2037-2041
21. Larkin R, Benjamin CD, Hsu YM, Li Q, Zukowski L, Silver RF: CD40 ligand (CD154) does not contribute to lymphocyte-mediated inhibition of virulent Mycobacterium tuberculosis within human monocytes. Infect Immun 2002, 70:4716-4720
22. Florido M, Goncalves AS, Gomes MS, Appelberg R: CD40 is required for the optimal induction of protective immunity to Mycobacterium avium. Immunology 2004, 111:323-327
23. Lazarevic V, Myers AJ, Scanga CA, Flynn JL: CD40, but not CD40L, is required for the optimal priming of T cells and control of aerosol M. tuberculosis infection. Immunity 2003, 19:823-835
24. Kwon-Chung KJ, Sorrell TC, Dromer F, Fung E, Levitz SM: Cryptococcosis: clinical and biological aspects. Med Mycol 2000, 38(Suppl 1):205-213
25. Shoham S, Levitz SM: The immune response to fungal infections. Br J Haematol 2005, 129:569-582
26. Hoang LMN, Maguire JA, Doyle P, Fyfe M, Roscoe DL: Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 2004, 53:935-940
27. Hofman V, Venissac N, Mouroux C, Butori C, Mouroux J, Hofman P: [Disseminated pulmonary infection due to Cryptococcus neoformans in a nonimmunocompromised patient]. French. Ann Pathol 2004, 24:187-191
28. Zahra LV, Azzopardi CM, Scott G: Cryptococcal meningitis in two apparently immunocompetent Maltese patients. Mycoses 2004, 47:168-173
29. Chen GH, McDonald RA, Wells JC, Huffnagle GB, Lukacs NW, Toews GB: The γ interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans. Infect Immun 2005, 73:1788-1796
30. Herring AC, Hernandez Y, Huffnagle GB, Toews GB: Role and development of TH1/TH2 immune responses in the lungs. Semin Respir Crit Care Med 2004, 25:3-10
31. Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB: Induction of interleukin-12 and γ interferon requires tumor necrosis factor α for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect Immun 2002, 70:2959-2964
32. Hoag KA, Lipscomb MF, Izzo AA, Street NE: IL-12 and IFN-γ are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Mol Biol 1997, 17:733-739
33. Huffnagle GB, Lipscomb MF: Cells and cytokines in pulmonary cryptococcosis. Res Immunol 1998, 149:387-396; discussion 512-384
34. + T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol 1994, 55:35-42
35. Huffnagle GB, Toews GB, Burdick MD, Boyd MB, McAllister KS, McDonald RA, Kunkel SL, Strieter RM: Afferent phase production of TNF-α is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 1996, 157:4529-4536
36. Kawakami K, Qureshi MH, Zhang T, Koguchi Y, Yara S, Takeda K, Akira S, Kurimoto M, Saito A: Involvement of endogenously synthesized interleukin (IL)-18 in the protective effects of IL-12 against pulmonary infection with Cryptococcus neoformans in mice. FEMS Immunol Med Microbiol 2000, 27:191-200
37. Kawakami K, Tohyama M, Xie Q, Saito A: IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol 1996, 104:208-214
38. +) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J Immunol 1990, 144:1472-1477
39. Mody CH, Paine R, 3rd, Jackson C, Chen GH, Toews GB: CD8 cells play a critical role in delayed type hypersensitivity to intact Cryptococcus neoformans. J Immunol 1994, 152:3970-3979
40. Mody CH, Paine R, 3rd, Jackson CJ, Toews GB: CD8 cells mediate delayed hypersensitivity following intrapulmonary infection with Cryptococcus neoformans. Chest 1993, 103:118S
41. Arora S, Hernandez Y, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB: Role of IFN-γ in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J Immunol 2005, 174:6346-6356
42. Arora S, McDonald RA, Toews GB, Huffnagle GB: Effect of a CD4-depleting antibody on the development of Cryptococcus neoformans-induced allergic bronchopulmonary mycosis in mice. Infect Immun 2006, 74:4339-4348
43. Chen GH, McNamara DA, Hernandez Y, Huffnagle GB, Toews GB, Olszewski MA: Inheritance of immune polarization patterns is linked to resistance versus susceptibility to Cryptococcus neoformans in a mouse model. Infect Immun 2008, 76:2379-2391
44. Chen GH, Olszewski MA, McDonald RA, Wells JC, Paine R, 3rd, Huffnagle GB, Toews GB: Role of granulocyte macrophage colony-stimulating factor in host defense against pulmonary Cryptococcus neoformans infection during murine allergic bronchopulmonary mycosis. Am J Pathol 2007, 170:1028-1040
45. Hernandez Y, Arora S, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB: Distinct roles for IL-4 and IL-10 in regulating T2 immunity during allergic bronchopulmonary mycosis. J Immunol 2005, 174:1027-1036
46. Hoag KA, Street NE, Huffnagle GB, Lipscomb MF: Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am J Respir Cell Mol Biol 1995, 13:487-495
47. Huffnagle GB, Boyd MB, Street NE, Lipscomb MF: IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol 1998, 160:2393-2400
48. Gibson PG: Allergic bronchopulmonary aspergillosis. Semin Respir Crit Care Med 2006, 27:185-191
49. Herring AC, Falkowski NR, Chen GH, McDonald RA, Toews GB, Huffnagle GB: Transient neutralization of tumor necrosis factor α can produce a chronic fungal infection in an immunocompetent host: potential role of immature dendritic cells. Infect Immun 2005, 73:39-49
50. Milam JE, Herring-Palmer AC, Pandrangi R, McDonald RA, Huffnagle GB, Toews GB: Modulation of the pulmonary type 2 T cell response to Cryptococcus neoformans by intratracheal delivery of a tumor necrosis factor α-expressing adenoviral vector. Infect Immun 2007, 75:4951-4958
51. Bauman SK, Nichols KL, Murphy JW: Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses. J Immunol 2000, 165:158-167
52. Osterholzer JJ, Curtis JL, Polak T, Ames T, Chen GH, McDonald R, Huffnagle GB, Toews GB: CCR2 mediates conventional dendritic cell recruitment and the formation of bronchovascular mononuclear cell infiltrates in the lungs of mice infected with Cryptococcus neoformans. J Immunol 2008, 181:610-620
53. Osterholzer JJ, Surana R, Milam JE, Montano GT, Chen GH, Sonstein J, Curtis JL, Huffnagle GB, Toews GB, Olszewski MA: Cryptococcal urease promotes the accumulation of immature dendritic cells and a nonprotective T2 immune response within the lung. Am J Pathol 2009, 174:932-943
54. Siegemund S, Alber G: Cryptococcus neoformans activates bone marrow-derived conventional dendritic cells rather than plasmacytoid dendritic cells and down-regulates macrophages. FEMS Immunol Med Microbiol 2008, 52:417-427 (Pubitemid 351420760)
55. Wozniak KL, Vyas JM, Levitz SM: In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis. Infect Immun 2006, 74:3817-3824
56. Vecchiarelli A, Retini C, Pietrella D, Monari C, Kozel TR: T lymphocyte and monocyte interaction by CD40/CD40 ligand facilitates a lymphoproliferative response and killing of Cryptococcus neoformans in vitro. Eur J Immunol 2000, 30:1385-1393
57. Pietrella D, Lupo P, Perito S, Mosci P, Bistoni F, Vecchiarelli A: Disruption of CD40/CD40L interaction influences the course of Cryptococcus neoformans infection. FEMS Immunol Med Microbiol 2004, 40:63-70
58. Zhou Q, Gault RA, Kozel TR, Murphy WJ: Immunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosis. Infect Immun 2006, 74:2161-2168
59. Zhou Q, Gault RA, Kozel TR, Murphy WJ: Protection from direct cerebral cryptococcus infection by interferon-γ-dependent activation of microglial cells. J Immunol 2007, 178:5753-5761
60. Berkefeld J, Enzensberger W, Lanfermann H: Cryptococcus meningoencephalitis in AIDS: parenchymal and meningeal forms. Neuroradiology 1999, 41:129-133
61. Lee SC, Dickson DW, Casadevall A: Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol 1996, 27:839-847
62. Olszewski MA, Noverr MC, Chen GH, Toews GB, Cox GM, Perfect JR, Huffnagle GB: Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol 2004, 164:1761-1771
63. Casadevall A, Perfect JR: Cryptococcus neoformans. Human Cryptococcosis edited by A Casadevall and JR Perfect. Washington DC, ASM Press, 1998, 541 p, pp 407-456
64. Kovacs JA, Kovacs AA, Polis M, Wright WC, Gill VJ, Tuazon CU, Gelmann EP, Lane HC, Longfield R, Overturf G, et al.: Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985, 103:533-538
65. Zhang Y, Wang F, Tompkins KC, McNamara A, Jain AV, Moore BB, Toews GB, Huffnagle GB, Olszewski MA: Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am J Pathol 2009, 175:2489-2500
66. + lung dendritic cells in response to fungal infection results from the CCR2-mediated recruitment and differentiation of Ly-6Chigh monocytes. J Immunol 2009, 183:8044-8053
67. Wiley JA, Harmsen AG: CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. J Immunol 1995, 155:3525-3529
68. Bates JH, Rincon M, Irvin CG: Animal models of asthma. Am J Physiol Lung Cell Mol Physiol 2009, 297:L401-L410
69. Hogan SP, Mould A, Kikutani H, Ramsay AJ, Foster PS: Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergenspecific immunoglobulins. J Clin Invest 1997, 99:1329-1339
70. Hellings PW, Kasran A, Bullens D, Overbergh L, Mathieu C, Heremans H, Matthys P, Boon L, Jorissen M, Ceuppens JL: IL-10- and IL-12-independent down-regulation of allergic sensitization by stimulation of CD40 signaling. J Immunol 2006, 177:5138-5144
71. Chen YQ, Shi HZ: CD28/CTLA-4-CD80/CD86 and ICOS-B7RP-1 costimulatory pathway in bronchial asthma. Allergy 2006, 61:15-26
72. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35